These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 16903769)
21. Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Nakamura T; Ito M; Hashimoto J; Shinomiya K; Asao Y; Katsumata K; Hagino H; Inoue T; Nakano T; Mizunuma H; Osteoporos Int; 2015 Nov; 26(11):2685-93. PubMed ID: 26001561 [TBL] [Abstract][Full Text] [Related]
22. Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis. Reginster JY Expert Opin Pharmacother; 2005 Oct; 6(13):2301-13. PubMed ID: 16218890 [TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates for prevention of postmenopausal osteoporosis. Ravn P Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss. McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736 [TBL] [Abstract][Full Text] [Related]
26. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies. Cosman F; Borges JL; Curiel MD Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726 [TBL] [Abstract][Full Text] [Related]
27. Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Miller PD; Recker RR; Harris S; Silverman S; Felsenberg D; Reginster J; Day BM; Barr C; Masanauskaite D Osteoporos Int; 2014 Jan; 25(1):349-57. PubMed ID: 24136103 [TBL] [Abstract][Full Text] [Related]
28. Progression of efficacy with ibandronate: a paradigm for the development of new bisphosphonates. Zaidi M; Epstein S; Harris ST; Kohles JD; Chesnut CH Ann N Y Acad Sci; 2007 Nov; 1117():273-82. PubMed ID: 18056047 [TBL] [Abstract][Full Text] [Related]
29. Oral ibandronate significantly reduces the risk of vertebral fractures of greater severity after 1, 2, and 3 years in postmenopausal women with osteoporosis. Felsenberg D; Miller P; Armbrecht G; Wilson K; Schimmer RC; Papapoulos SE Bone; 2005 Nov; 37(5):651-4. PubMed ID: 16126016 [TBL] [Abstract][Full Text] [Related]
30. Ibandronate: A Review in Japanese Patients with Osteoporosis. Keating GM Drugs Aging; 2016 Apr; 33(4):295-303. PubMed ID: 26915075 [TBL] [Abstract][Full Text] [Related]
31. [Monthly ibandronate attachment to Mexican and Chilean women with osteoporosis, with or without a biofeedback strategy]. García-Hernández P; Carranza-Lira S; Motta-Martínez E Ginecol Obstet Mex; 2010 Jun; 78(6):322-8. PubMed ID: 20939245 [TBL] [Abstract][Full Text] [Related]
32. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study. Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582 [TBL] [Abstract][Full Text] [Related]
33. Significance of a decline in bone mineral density while receiving oral bisphosphonate treatment. Sebba AI Clin Ther; 2008 Mar; 30(3):443-52. PubMed ID: 18405784 [TBL] [Abstract][Full Text] [Related]
34. Use of bisphosphonates in the management of postmenopausal osteoporosis. Papapoulos SE Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. Eisman JA; Civitelli R; Adami S; Czerwinski E; Recknor C; Prince R; Reginster JY; Zaidi M; Felsenberg D; Hughes C; Mairon N; Masanauskaite D; Reid DM; Delmas PD; Recker RR J Rheumatol; 2008 Mar; 35(3):488-97. PubMed ID: 18260172 [TBL] [Abstract][Full Text] [Related]
36. Ibandronate: a review of its vertebral and nonvertebral antifracture efficacy. Amling M; Kurth A Womens Health (Lond); 2009 Sep; 5(5):467-73. PubMed ID: 19702445 [TBL] [Abstract][Full Text] [Related]
37. Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety. Epstein S; Delmas PD; Emkey R; Wilson KM; Hiltbrunner V; Schimmer RC Maturitas; 2006 Apr; 54(1):1-10. PubMed ID: 16522358 [TBL] [Abstract][Full Text] [Related]
38. Effects of ibandronate on bone quality: preclinical studies. Bauss F; Dempster DW Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333 [TBL] [Abstract][Full Text] [Related]
39. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial. Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L; Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768 [TBL] [Abstract][Full Text] [Related]